| __timestamp | Dynavax Technologies Corporation | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 55305000 |
| Thursday, January 1, 2015 | 86943000 | 77593000 |
| Friday, January 1, 2016 | 84493000 | 50013000 |
| Sunday, January 1, 2017 | 64988000 | 58914000 |
| Monday, January 1, 2018 | 74951000 | 65927000 |
| Tuesday, January 1, 2019 | 62331000 | 59815000 |
| Wednesday, January 1, 2020 | 28607000 | 56188000 |
| Friday, January 1, 2021 | 32228000 | 53012000 |
| Saturday, January 1, 2022 | 46600000 | 32815000 |
| Sunday, January 1, 2023 | 54886000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Unleashing the power of data
In the dynamic world of biotechnology, innovation is the lifeblood of progress. Mesoblast Limited and Dynavax Technologies Corporation, two prominent players, have been investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Dynavax consistently led the charge, with R&D expenses peaking in 2015, when they invested approximately 70% more than Mesoblast. However, Mesoblast has shown resilience, narrowing the gap significantly by 2018, when their R&D spending was just 12% less than Dynavax.
The trend took a turn in 2020, as Dynavax's R&D expenses dropped by nearly 55% from their 2015 peak, while Mesoblast maintained a steadier course. By 2023, Dynavax's investment rebounded slightly, yet Mesoblast's spending continued to decline. This fluctuation highlights the volatile nature of biotech investments, where strategic shifts and market conditions can dramatically alter the landscape.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Mesoblast Limited
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Analyzing R&D Budgets: Novartis AG vs Dynavax Technologies Corporation
Analyzing R&D Budgets: Zoetis Inc. vs Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Comparing Innovation Spending: Ascendis Pharma A/S and Mesoblast Limited
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Amneal Pharmaceuticals, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Mesoblast Limited
Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?
R&D Insights: How Mesoblast Limited and Celldex Therapeutics, Inc. Allocate Funds